February 2011

The Push and Pull of Patient Recruitment

January 26, 2011

There are two sides to patient recruitment: the “push” (advertising) and the “pull” (referral management to randomization). While many companies focus a lot of effort on the push side of recruitment, the importance of the pull can often be overlooked. Yet this is where the rubber meets the road. The push encourages people to take […]

Achieving More Precise Patient Recruitment

January 26, 2011

While pharmaceutical market researchers have benefited from comprehensive, secondary data sources and sophisticated analytics for years, the R&D functions and clinical research organizations (CROs) were on the outside looking in when it came to access to this information and analytical approach. However, today R&D pharma executives and CROs can tap into these rich data resources […]

Global Patient Recruitment: Preventing Delays Through Knowledge Application

January 26, 2011

Enrollment of clinical trial subjects in far-ranging global destinations has become desirable for many drug developers. Generally, these regions offer a large pool of relatively treatment-naïve patients, GCP-standard medical facilities, capable health care professionals and a substantially lower cost to conduct clinical studies. The varying regulatory and ethical requirements, complicated by medical, cultural and political […]

SHOWCASE FEATURE: Unclogging the Patient Recruitment Bottleneck

January 26, 2011

The increased complexity of clinical trial design and the trend toward more targeted patient populations necessitates rethinking the traditional methods of patient recruitment to ­overcome failure and timeline extensions. Patient recruitment remains to be one of the biggest, and most costly, bottlenecks in clinical development. While the most commonly accepted recruitment mainstays are investigative site […]

Emerging Market: China

January 26, 2011

Whether it is partnering, acquisitions, or the expansion of operations, China spells opportunity for the pharmaceutical industry. Increasingly, global pharmaceutical companies are either expanding their own operations within China or choosing to partner with China-based companies. According to IMS Health, China is expected to become the world’s third-largest prescription drug market in 2011 and the […]

M&A: A Short-Term Solution Whose Time May Be Over

January 26, 2011

2009 was punctuated by the latest and greatest round of major pharmaceutical company mergers, with the big three — Merck and Schering-Plough, Pfizer and Wyeth, and Roche and Genentech — shining a spotlight on M&A practices in the industry. In reality, M&A has always been a growth strategy for life-sciences companies, enabling them to add […]

Digital Marketing: Dare to be Different

January 26, 2011

Research shows creativity is one of the most important components of a successful campaign, however, our experts say there are several other elements behind a campaign that need to be present to make the best of what digital media have to offer. Among them are matching the audience with the most appropriate channel and thoroughly […]

The Era of Proactive Safety

January 26, 2011

Process, people, and technology have to align to ­enable a truly proactive risk-management and ­pharmacovigilance program that protects patients. First, do no harm. This is medicine’s highest ethical standard, an oath physicians take when they begin to practice. In the last few years, dangerous side effects of blockbuster products and some high-profile product withdrawals have […]

Developing A True Strategic Partnership

January 26, 2011

The biopharmaceutical industry is facing intense pressure within research and development to bring new drugs to the market at a time when drug development has become complex and expensive. Blockbuster patent expirations, more complex protocols, increasing R&D costs, patient recruitment issues, and more stringent regulatory and safety issues are all challenging drug developers. As a […]

Last Word

January 26, 2011

PV: What should the goals of a corporate social media program be? Adler: There are many opportunities for companies to engage in social media; generally these fall into three categories. Certainly, chief among the reasons to embark upon a proactive social media program is to enhance awareness among a company’s key patient, investor, healthcare professional, […]

Talent Pool

January 26, 2011

Pharmaceutical POOL Robert DAVIS Dr. Ludwig HANTSON Baxter International Forms Medical Products Business Baxter International has appointed Robert Davis corporate VP and president of its newly created medical products business, which combines the company’s renal and medication delivery businesses into a single global business unit. Mr. Davis previously served as corporate VP and president of […]

Social Media

January 26, 2011

Pharma is Using Social Media, With Reservations Trend Watch: More than 65% of life-sciences company professionals say their company uses or plans to use social networks at a company level, according to a report by Deloitte. Social Media Leveraging Online Social ­Networks Innovative companies are beginning to leverage online social networks of physicians, patients, and […]

Tools of the Trade

January 26, 2011

New Platforms Streamline Scientific Data Sharing Trends: Service providers are harnessing the power of user-generated applications and SaaS to help take scientific search and discovery to the next level.   Elsevier’S SCIVERSE APPLICATIONS beta, a new module within the SciVerse content database platform, consists of more than a dozen applications created by academic and commercial […]

What’s New

January 26, 2011

Trend: As the healthcare industry continues to consolidate and rationalize, pharma and biotech companies increasingly need a communications partner that understands how to reach both ­professional and consumer audiences across traditional and digital channels. New Focus on Digital Healthcare Strategies What’s New HEALIX DIGITAL HEALTH, a new joint-venture agency, combines the marketing expertise of two […]

PharmaTrax

January 26, 2011

Trend: With its traditional business model breaking down amid scant financing and lengthy R&D processes, the biotech sector needs to reinvent itself by adopting a more collaborative ­approach to capitalize on emerging healthcare opportunities. According to the PricewaterhouseCoopers (PwC) report — Biotech Reinvented: Where do you go from here? — the new biotech business model […]

UpFront

January 26, 2011

Awards… Cephalon wins PRSA Awards CRF Health Wins at Clio Natrel Wins Rx Club Award INDUSTRY at Large Smarty Apps… E-Promotion on the E-Rise Supporting Science Education Lucky 14 Pharma Saves Green by Going Green Disruptive Technology, Disruptive times Top Innovators Podcasts Best Practices for Your CRO ­Partnerships Thought Leader: Colin Terry, Aptuit A New […]

Letter from the Editor

January 26, 2011

Pharma 3.0: Are you ready? The era of Pharma 3.0 is upon us. According to Ernst & Young (EY), several industry trends, including healthcare reform, health IT, comparative effectiveness, and the rising confidence in consumer power, are driving nontraditional companies into the life-sciences sector. These factors, among others, will continue to prompt pharmaceutical companies to […]

FEEDBACK